Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects

NCT07588646 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: HEC585
DRUG: Nintedanib
DRUG: Pirfenidone

Sponsor

Sunshine Lake Pharma Co., Ltd.